NRXP Earnings Prediction
The chart below shows how NRXP performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NRXP sees a -1.95% change in stock price 10 days leading up to the earnings, and a -1.32% change 10 days following the report. On the earnings day itself, the stock moves by +0.61%. This data can give you a slight idea of what to expect for the next quarter's release.
NRXP Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.15
-114.29%
-80.00%
No Data Available
NRXP Earnings Analysis
NRX Pharmaceuticals, Inc. Common Stock Corporation (NRXP.O) Earnings Conference Call
Positive
Operating Loss Reduction: NRx Pharmaceuticals reduced its operating net loss by nearly 75% year-over-year from $6.1 million in the third quarter to $1.6 million in 2024.
R&D Expense Reduction: Research and development expenses decreased from $3.3 million in 2023 to $0.6 million in 2024, representing a significant reduction in costs.
Suicidal Ideation Reduction: The company achieved a 50% reduction in suicidal ideation in numerous trials and real-world settings, demonstrating the effectiveness of its treatments.
Acquisition Financing Commitment: NRx Pharmaceuticals has received initial non-binding commitments from lenders for non-dilutive acquisition financing of Hope clinics, indicating strong financial backing.
Revenue Growth Projections: The company expects to generate $25 million in revenue by the end of this year and over $100 million by the end of next year, showcasing robust growth projections.
Negative
Operating Loss Reduction: NRx Pharmaceuticals reduced its operating net loss by nearly 75% year-over-year from $6.1 million in the third quarter to $1.6 million in 2024.
R&D Expense Reduction: Research and development expenses decreased from $3.3 million in 2023 to $0.6 million in 2024, indicating a significant reduction in investment in this area.
Expense Reduction Overview: The $2.7 million decrease in expenses is primarily related to a $2.1 million reduction in clinical trial and development expenses due to the conclusion of the Phase IIb/III study.
Net Loss Reduction: For the nine-month period ended September 30, 2024, NRx reduced its net loss to $16.1 million compared to $25.8 million in the prior year, reflecting ongoing financial challenges.
Administrative Expense Reduction: The company achieved a slight decrease in general and administrative expenses from $12.3 million in 2023 to $10.9 million in 2024, representing an 11% year-over-year decline.
NRXP FAQs
How does NRXP typically perform around its earnings report dates?
Is NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NRXP Earning Call Sentiment
NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
NRXP.O
-6.94%Positive
The earnings call summary reveals significant progress in reducing net losses and securing new funding, along with optimistic projections for profitability and revenue growth in Hope Therapeutics. The Q&A section, however, highlights some uncertainties in revenue recognition and clinic acquisition. NULLtheless, the overall sentiment is positive due to strategic funding, debt retirement, and strong future revenue projections. Despite some uncertainties, the positive outlook for profitability and revenue growth, along with the potential for accelerated drug approval, suggests a positive stock price movement in the next two weeks.
